Expert Perspective|Professor Jinjun Chen on Non-Invasive Diagnosis of Portal Hypertension in Patients with Advanced Chronic Liver Disease

Expert Perspective|Professor Jinjun Chen on Non-Invasive Diagnosis of Portal Hypertension in Patients with Advanced Chronic Liver Disease

Complications related to portal hypertension are the main cause of death in patients with advanced chronic liver disease (ACLD). Even after the underlying cause is controlled, clinical events during the progression of portal hypertension, such as esophageal variceal bleeding, ascites, overt hepatic encephalopathy, and acute-on-chronic liver failure, are the most critical factors leading to high mortality in chronic liver disease. The hepatic venous pressure gradient is the "gold standard" for assessing portal hypertension, and upper gastrointestinal endoscopy is an essential tool for screening and evaluating esophagogastric varices and their severity. However, both are invasive procedures, making them unsuitable for screening and monitoring portal hypertension. Non-invasive diagnostic methods based on spleen stiffness measurement (SSM) using vibration-controlled transient elastography can be used for screening, stratifying diagnosis, and monitoring portal hypertension and esophageal varices. At the recent 2024 Jinling Liver Disease Conference, Professor Jinjun Chen from Nanfang Hospital, shared advances in the non-invasive diagnosis of portal hypertension and esophagogastric varices in ACLD patients using spleen stiffness. The content is summarized as follows for the readers.
From Inoperable to Surgical Resection——Transformative Treatments Bring New Hope for Advanced Liver Cancer Patients

From Inoperable to Surgical Resection——Transformative Treatments Bring New Hope for Advanced Liver Cancer Patients

To help clinicians and researchers in the field of hepatology stay updated with academic knowledge and research trends, Hepatology Digest and the Journal of Clinical and Translational Hepatology (JCTH) jointly launched the "Journal Club" column. Every two weeks (Tuesday), one selected article is highlighted, focusing on key points or insights to improve clinical practice, inspire research thinking, and enhance writing skills.
“CARTITUDE-2 Phase II Update: Cilta-cel for Multiple Myeloma Post 1-3 Prior Therapies or Early Relapse”

“CARTITUDE-2 Phase II Update: Cilta-cel for Multiple Myeloma Post 1-3 Prior Therapies or Early Relapse”

From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting was grandly held in Glasgow, UK, a city renowned for its historical significance. This year marks the 50th anniversary of EBMT, and the event gathered leading figures in the field of hematopoietic stem cell transplantation and over 6,000 hematology experts from around the world. The attendees reviewed the remarkable achievements in the fields of hematology and bone marrow transplantation over the past 50 years and explored forward-looking patient management strategies. At the conference, chimeric antigen receptor T-cell (CAR-T) therapy, a highlight of this meeting, showcased a series of breakthroughs in the treatment of multiple myeloma and lymphoma, attracting significant attention. This issue features a special invitation to Professor Jun Ma from the Harbin Institute of Hematological Oncology to provide an insightful interpretation of five major research studies in the field of CAR-T cell therapy. Here, we present a compilation of these insights for our readers.
EAU24 On-Site Highlights | Dr. Zedan Zhang of Professor Kan Gong’s Team on Perioperative Immunotherapy Strategies for MIBC

EAU24 On-Site Highlights | Dr. Zedan Zhang of Professor Kan Gong’s Team on Perioperative Immunotherapy Strategies for MIBC

Radical cystectomy (RC) and pelvic lymph node dissection (PLND) are standard treatments for muscle-invasive bladder cancer (MIBC), yet distant metastasis remains a challenge for some patients. Exploring perioperative treatment options for MIBC is crucial to improve patient outcomes. At the 39th Annual European Association of Urology (EAU24) Congress in Paris, France, "Oncology Frontier" invited Dr. Zedan Zhang from Professor Kan Gong’s team at Peking University First Hospital to discuss the latest advancements in MIBC perioperative treatment.
Dr. Ruiyi Deng of Professor Kan Gong’s Team on the Re-definition and Value of Small Renal Masses by the EAU Guidelines Panel

Dr. Ruiyi Deng of Professor Kan Gong’s Team on the Re-definition and Value of Small Renal Masses by the EAU Guidelines Panel

In recent years, numerous breakthroughs have been made in the field of renal tumors. The EAU Guidelines Panel continually incorporates new research data and evidence-based medicine to revise and update the EAU guidelines. At the 39th Annual European Association of Urology (EAU24) Congress held in Paris, France, "Oncology Frontier" invited Dr. Ruiyi Deng from Professor Kan Gong's team at Peking University First Hospital to discuss the redefinition of small renal masses (SRMs) and the value of active surveillance.
2024 Southern-Northern Summit丨Academician Binghe Xu : Progress and Future of Clinical Research in Breast Cancer

2024 Southern-Northern Summit丨Academician Binghe Xu : Progress and Future of Clinical Research in Breast Cancer

With the continuous development of medicine and science and technology, the field of breast cancer treatment has seen new breakthroughs. We have witnessed an increasing number of new discoveries and research advancements gradually being applied in clinical practice. These achievements not only enhance the efficiency of breast cancer diagnosis and treatment but also bring more possibilities for breast cancer patients to return to normal life. At the 2024 Southern-Northern Summit, Academician Binghe Xu from the Cancer Hospital of the Chinese Academy of Medical Sciences presented a report on "Progress and Future of Clinical Research in Breast Cancer," sharing current screening and treatment advancements, and experiences from clinical research at the Cancer Hospital of the Chinese Academy of Medical Sciences. This article reviews his insights.